Long-term Surveillance Registry for Biologics (HUMIRA).

Trial Profile

Long-term Surveillance Registry for Biologics (HUMIRA).

Phase of Trial: Phase IV

Latest Information Update: 13 Jun 2014

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HUMIRA
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Sep 2012 Planned number of patients changed from 5738 to 5742.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top